Across 88 bladder/urothelial Phase II and III trial records in Europe, 54 trials listed CRO or outsourced-provider support, equal to 61.4%. CRO-supported trials carried a disproportionate operating load: 313 of 392 CTIS country-level records (79.8%), 1,909 of 2,526 sites (75.6%), and 8,683 of 14,021 planned participants (61.9%). Almac was the most active provider family by trial count, appearing in 18 of 54 CRO-supported trials (33.3%), followed by ICON in 13 (24.1%), Parexel and PPD/Thermo Fisher in 12 each (22.2%).
Among 54 CRO-supported trials, Almac appeared most often (18/54, 33.3%). ICON followed with 13/54 (24.1%), while Parexel and PPD/Thermo Fisher each appeared in 12/54 (22.2%). Provider names are normalized at family level, and each trial is counted once per provider family.
The leading providers are not only classic full-service CROs; they also include clinical-supply, eClinical, imaging, laboratory, and data-capture vendors. This reflects a bladder/urothelial outsourcing pattern where CTIS submission work, biomarker logistics, randomization, imaging review, and patient-reported data capture are often split across multiple specialist providers.
CRO support increased most clearly with CTIS country complexity: 6/6 trials with 11+ countries had CRO support (100.0%), compared with 7/30 single-country trials (23.3%). Site load also mattered: 25/32 trials with 31+ sites were CRO-supported (78.1%). Participant count was a weaker signal, with the highest CRO rate in the 150–299 participant band (11/16, 68.8%).
| 1 country | 7/30 | 23.3% |
| 2–3 countries | 10/14 | 71.4% |
| 4–6 countries | 14/17 | 82.4% |
| 7–10 countries | 17/21 | 81.0% |
| 11+ countries | 6/6 | 100.0% |
| 0–5 sites | 7/15 | 46.7% |
| 6–15 sites | 12/26 | 46.2% |
| 16–30 sites | 10/15 | 66.7% |
| 31+ sites | 25/32 | 78.1% |
| <50 participants | 11/17 | 64.7% |
| 50–149 participants | 23/38 | 60.5% |
| 150–299 participants | 11/16 | 68.8% |
| 300+ participants | 9/17 | 52.9% |
| 1 listed disease | 22/42 | 52.4% |
| 2–3 listed diseases | 19/28 | 67.9% |
| 4+ listed diseases | 13/18 | 72.2% |
CRO need is driven more by CTIS country coordination and site footprint than by participant count alone. The practical threshold appears around 4+ countries or 31+ sites, where CRO support rates moved above 78% in the dataset.
Upper-tract urothelial carcinoma had the highest CRO rate (4/4, 100.0%), followed by mixed solid-tumor basket studies that included urothelial cancer (12/16, 75.0%) and advanced/metastatic urothelial or bladder cancer (11/15, 73.3%). Non-muscle-invasive or BCG-unresponsive bladder cancer was lower, with 9/18 CRO-supported trials (50.0%).
The highest CRO reliance appears in narrower or more operationally complex settings: upper-tract disease, basket trials, and advanced/metastatic urothelial cancer. These studies typically create additional operational pressure through multi-country screening, biomarker work, imaging review, and CTIS Part II coordination.
The most common outsourced function was central laboratory, biomarker, PK/PD, and sample analysis work, present in 47/88 trials (53.4%). Clinical operations, project/vendor management, and CTIS support appeared in 45/88 (51.1%), followed by IRT/RTSM, randomization, and drug assignment in 35/88 (39.8%).
Bladder/urothelial outsourcing is concentrated around evidence-generation infrastructure rather than simple recruitment alone. Biomarker/sample logistics and clinical operations/CTIS support each appeared in roughly half of all trials, making them the clearest service-demand areas for CRO and specialist vendor positioning.
Spain was the largest CTIS operating market in the cohort, appearing in 67 trial-country records with 650 sites and 3,558 participants. France followed with 53 records, 482 sites, and 2,643 participants. CRO-supported trials accounted for 313/392 CTIS country-level records (79.8%), showing that EU submission and country coordination are central drivers of outsourcing need.
| Country | Trials | Sites | Participants | CRO share |
|---|---|---|---|---|
| Spain | 67 | 650 | 3,558 | 76.1% |
| France | 53 | 482 | 2,643 | 81.1% |
| Italy | 46 | 361 | 1,620 | 76.1% |
| Germany | 32 | 291 | 965 | 81.2% |
| Belgium | 29 | 111 | 615 | 82.8% |
| Poland | 27 | 155 | 934 | 77.8% |
| Netherlands | 21 | 75 | 475 | 71.4% |
| Czechia | 16 | 55 | 201 | 87.5% |
| Greece | 16 | 54 | 241 | 100.0% |
| Denmark | 13 | 35 | 118 | 92.3% |
The commercial CRO opportunity is most concentrated in Spain, France, Italy, Germany, Belgium, and Poland. These six countries together represented 254 country-level trial records, 2,050 sites, and 10,335 planned participants, making them the core EU/EEA operational footprint for bladder/urothelial Phase II–III work.
The top site-level signal was heavily concentrated in Spain, France, and Italy. Hospital Universitario 12 De Octubre appeared in 44 trials, Hospital Universitari Vall D Hebron in 33, and Institut Gustave Roussy in 30. This indicates that CRO/site-activation expertise around a relatively small set of recurrent uro-oncology hubs may create leverage across multiple sponsors.
| Site | Country | Trial appearances |
|---|---|---|
| Hospital Universitario 12 De Octubre | Spain | 44 |
| Hospital Universitari Vall D Hebron | Spain | 33 |
| Institut Gustave Roussy | France | 30 |
| Hospital Universitario La Paz | Spain | 26 |
| Hospital Universitario Marques De Valdecilla | Spain | 25 |
| Fondazione IRCCS Istituto Nazionale Dei Tumori | Italy | 25 |
| Ospedale San Raffaele S.r.l. | Italy | 24 |
| Hospital Clinic De Barcelona | Spain | 23 |
| Hospital Clinico San Carlos | Spain | 22 |
| Hospital Universitario Ramon Y Cajal | Spain | 21 |
For CROs selling bladder/urothelial trial support, the strongest adjacent opportunity is not only sponsor-level coverage but repeated execution at high-frequency sites. The top 10 sites together accounted for 273 trial appearances, creating a clear site-network advantage for feasibility, activation, contracting, and CTIS Part II document coordination.
The bladder/urothelial Phase II–III CRO opportunity in Europe is strongest when the trial is multi-country, multi-site, biomarker-heavy, or requires repeated CTIS Part II coordination. Almac, ICON, Parexel, PPD/Thermo Fisher, Bioclinica/Clario, and IQVIA form the most visible provider set by trial count and operating footprint. The most attractive service lines are central laboratory/biomarker/PK support, CTIS-linked clinical operations, IRT/RTSM, imaging review, and ePRO/eCOA capture.
CRO: Contract research organization or CTIS-listed outsourced provider supporting trial execution.
CTIS: Clinical Trials Information System used for EU clinical trial submissions and country-level authorization workflows.
Part II: The country-specific CTIS submission component covering national and site-related documentation.
IRT/RTSM: Interactive response technology/randomization and trial supply management.
ePRO/eCOA and PK/PD: Electronic patient-reported/clinical outcome assessments and pharmacokinetic/pharmacodynamic analysis.